Sisira Santhosh
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Sisira Santhosh has a total of 3 co-authors. Here are the top co-authors by number of shared publications:
- Arvind Kunadi
Internal Medicine/Nephrology, McLaren Health Care, Flint/Michigan State University (MSU), Michigan, USA
1 shared publication - Atefeh Kalantary
Internal Medicine, McLaren Health Care/Michigan State University (MSU), Flint, USA
1 shared publication - Bilal Malik
Internal Medicine, McLaren Health Care, Michigan State University, Flint, USA
1 shared publication
Latest Publications
- Open Access
- 5 July 2022
- Published by Springer Nature in Cureus
- Vol. 14 (7) , e26582
Immune Thrombocytopenic Purpura (ITP) Following Natural COVID-19 Infection
Immune thrombocytopenic purpura (ITP) has been linked to the COVID-19 vaccine series as a rare adverse event but has recently emerged in the literature as a sequela of natural COVID-19 infection. ITP is a diagnosis of exclusion where a diagnosis is made by having isolated thrombocytopenia (platelet count <100,000/μL) and no other identifiable etiology for the thrombocytopenia. We share the case of a young male without any history of hematological or immunological disorders presenting with severe, symptomatic thrombocytopenia following a natural COVID-19 infection. Patients should be made aware of the potential risk of adverse events with not only vaccination but also even mild cases of natural infection with COVID-19. An emphasis should be placed on the fact that the benefits of vaccination continue to outweigh the potential risks of adverse events, even in those with a pre-existing diagnosis of ITP.
- 5 July 2022
- Published by Springer Nature in Cureus
- Vol. 14 (7) , e26582
Open AccessImmune Thrombocytopenic Purpura (ITP) Following Natural COVID-19 Infection
Immune thrombocytopenic purpura (ITP) has been linked to the COVID-19 vaccine series as a rare adverse event but has recently emerged in the literature as a sequela of natural COVID-19 infection. ITP is a diagnosis of exclusion where a diagnosis is made by having isolated thrombocytopenia (platelet count <100,000/μL) and no other identifiable etiology for the thrombocytopenia. We share the case of a young male without any history of hematological or immunological disorders presenting with severe, symptomatic thrombocytopenia following a natural COVID-19 infection. Patients should be made aware of the potential risk of adverse events with not only vaccination but also even mild cases of natural infection with COVID-19. An emphasis should be placed on the fact that the benefits of vaccination continue to outweigh the potential risks of adverse events, even in those with a pre-existing diagnosis of ITP.